ELN vs. IPSS-M in MDS/AML: Which Prognostic System Should Guide Clinical Decision-Making?

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Comparative Analysis of ICC and WHO Classifications Reveals Molecular and Clinical Convergence Between AML-MR and MDS/AML.2026 · 2 citations
2. 2Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification2024 · 7 citations
3. 3Distinctive Molecular Risk Factors Between <scp>MDS</scp> and <scp>MDS</scp> / <scp>AML</scp> Defined by <scp>ICC</scp>2026 · 1 citations
4. 4Limited prognostic value of ELN classification and relevance of molecular ontogeny in acute myeloid leukemia post myeloproliferative neoplasms: a retrospective multicenter study2026
5. 5Clinico‐genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification2023 · 15 citations